InMed Pharmaceuticals Inc. reported its financial results for the three months ending September 30, 2025, revealing a revenue of $1.12 million, a decrease of 11% from $1.26 million in the same period last year. The company's gross profit also fell to $403,159, down from $493,413, reflecting a decline in sales and increased competition in the market for bulk rare cannabinoids. The net loss for the quarter was $1.73 million, slightly higher than the $1.68 million loss reported in the prior year, resulting in a net loss per share of $0.44 compared to $2.71 in the previous year.
InMed's total operating expenses for the quarter were $2.22 million, a marginal decrease from $2.23 million in the same period last year. Research and development expenses decreased by 17% to $581,612, attributed to reduced external contractor costs, although personnel compensation increased. General and administrative expenses rose slightly to $1.53 million, reflecting higher salaries and marketing expenses. The company’s cash and cash equivalents stood at $9.33 million as of September 30, 2025, down from $11.08 million at the end of June 2025.
The company has made strategic moves, including the appointment of two new directors, Neil Klompas and John Bathery, who bring extensive experience in healthcare and biotechnology. This change is expected to enhance InMed's operational and strategic capabilities. Additionally, InMed continues to focus on its product pipeline, which includes drug candidates targeting Alzheimer’s disease and other conditions, while also developing proprietary manufacturing technologies through its subsidiary, BayMedica.
Operationally, InMed reported a decrease in customer concentration risk, with the top customer accounting for 25% of revenues, down from 22% in the previous year. The company is actively pursuing partnerships and collaborations to enhance its market position and product offerings. However, it faces significant challenges, including the need for additional financing to support ongoing operations and research, as indicated by its accumulated deficit of approximately $119 million.
Looking ahead, InMed anticipates continued operating losses and negative cash flows, with expectations to fund operations through equity and debt financing. The company has expressed substantial doubt about its ability to continue as a going concern within the next year, emphasizing the importance of securing additional capital to sustain its operations and advance its product development initiatives.
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals develops proprietary small molecule drug candidates targeting the endocannabinoid system to treat high unmet medical needs such as Alzheimer’s disease, dry AMD, and epidermolysis bullosa. The company combines innovative research with diverse manufacturing approaches, including biosynthesis and proprietary platforms, to develop and commercialize pharmaceutical and wellness products. Its core focus is on neuroprotection, anti-inflammatory therapies, and rare cannabinoids for medical and health sectors.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.